Lyra Therapeutics (LYRA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Supplement amends the definitive proxy statement for the 2025 Annual Meeting of Stockholders.
Proxy solicitation is being conducted for the annual meeting, with a focus on key governance and voting matters.
Voting matters and shareholder proposals
Proxies are being solicited for the 2025 Annual Meeting, with materials furnished to stockholders.
Board of directors and corporate governance
Board of Directors is actively involved in the solicitation of proxies for the annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Lyra Therapeutics
- Proposals include director elections, auditor ratification, and a reverse stock split to maintain listing.LYRA
Proxy Filing2 Dec 2025 - Key votes include director elections, auditor ratification, and a reverse stock split to support Nasdaq compliance.LYRAProxy Filing2 Dec 2025
- Key votes include director elections, auditor ratification, and a flexible reverse stock split.LYRAProxy Filing2 Dec 2025
- Registering 846,744 shares for resale from warrants after positive Phase 3 CRS trial.LYRARegistration Filing29 Nov 2025
- Positive Phase 3 data and cost cuts, but urgent funding and Nasdaq risks remain.LYRAQ3 202512 Nov 2025
- LYR-210 achieved significant efficacy and safety in ENLIGHTEN 2, supporting regulatory submission.LYRAStudy Result10 Nov 2025
- Net loss narrowed, costs cut, and strong Phase 3 data, but funding and regulatory risks remain.LYRAQ2 202512 Aug 2025
- LYR-210 demonstrated strong Phase 3 efficacy and safety, advancing toward regulatory submission.LYRACorporate Presentation3 Jul 2025
- Q3 net loss narrowed to $11.9M, but viability is uncertain pending 2025 trial results.LYRAQ3 202413 Jun 2025